Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
02/07/26	€1.165	+1.30%	14,000
01/07/26	€1.150	-2.54%	11,000
30/06/26	€1.180	+0.85%	3,000
29/06/26	€1.170	+1.30%	50,000
26/06/26	€1.155	+0.87%	11,000

Real-time Borsa Italiana

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Borsa Italiana Other stock markets 16:45:00 02/07/2026 BST			5-day change	1st Jan Change
1.165 ^EUR	+1.30%		+2.19%	-20.75%

06-29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN
06-22	Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares	AN

Market Cap	9.93M 11.36M 9.11M 8.5M 16.11M 1.08B 16.39M 110M 42.53M 530M 42.65M 41.73M 1.83B	P/E 2024	30.8x	P/E 2025	17x
Enterprise Value	10.22M 11.7M 9.39M 8.75M 16.59M 1.11B 16.87M 113M 43.8M 546M 43.92M 42.97M 1.88B	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	18.98%	Yield 2024 *	-	Yield 2025	-

06-29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN
06-22	Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares	AN
06-15	Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares	AN
06-04	Equities trend higher; banks lead gains on the MIB	AN
05-22	European markets rebound; STM and Stellantis lead gains	AN
05-21	Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year	AN
05-21	Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln	RE
05-21	European markets set for lower open; focus on manufacturing PMIs	AN
04-20	Brent rebounds; futures signal risk-off sentiment	AN
04-17	Greenlight on Hormuz sparks global equity rally	AN
04-12	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Laboratorio Farmaceutico Erfo posts triple-digit profit growth in 2025	AN
03-06	IG Futures Point to Higher European Markets	AN

04-09	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
21/10/25	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
29/08/25	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
04/06/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
19/05/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

Laboratorio Farmaceutico Erfo S.p.A. Share Price

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation: Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases: Laboratorio Farmaceutico Erfo S.p.A.

News in other languages: Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-29	Laboratorio Farmaceutico Erfo rileva 14.000 azioni proprie
06-22	Erfo prosegue coi buyback e riacquista 28.000 azioni
06-15	Laboratorio Farmaceutico Erfo acquista 15.000 azioni proprie
06-04	Borse rialziste; bene i bancari sul MIB
05-22	Tornano gli acquisti in Europa; su STM e Stellantis

1 day	+1.30%
1 week	+2.19%
Current month	-1.27%
1 month	+5.43%
3 months	+4.48%
6 months	-20.75%
Current year	-20.75%

1 week	1.12	1.19
1 month	1.07	1.19
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	56	31/12/2012
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	56	31/12/2012
Flavio Corpina BRD	Director/Board Member	47	31/12/2016
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
12-15	Alessandro Cutè	Sell	Chief Executive Officer	322,000	3.5778%
12-15	Alessandro Cutè	Sell	Chief Executive Officer	968,000	10.7556%
28/06/22	Alessandro Cutè	Others	Chief Executive Officer	300,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	+1.30%	+2.19%	-14.34%	+6.88%	11.16M
ELI LILLY AND COMPANY	+1.86%	+7.34%	+55.34%	+162.34%	1,063B
JOHNSON & JOHNSON	+3.57%	+7.42%	+69.09%	+61.03%	611B
ABBVIE INC.	+3.99%	+7.38%	+36.87%	+93.38%	444B
ROCHE HOLDING AG	+4.17%	-0.96%	+26.12%	+20.22%	324B
ASTRAZENECA PLC	+4.94%	+4.51%	+39.76%	+28.93%	285B
NOVARTIS AG	+2.42%	+2.96%	+30.77%	+42.24%	283B
NOVO NORDISK A/S	+2.47%	+6.56%	-24.26%	-39.60%	219B
AMGEN INC.	+3.55%	+6.05%	+26.04%	+66.28%	195B
GILEAD SCIENCES, INC.	+4.21%	+6.00%	+17.72%	+71.11%	156B
Average	+3.16%	+2.63%	+26.31%	+51.28%	358.07B
Weighted average by Cap.	+2.97%	+4.16%	+41.47%	+81.94%

	2024	2025
Net sales	6.03M 6.9M 5.54M 5.17M 9.79M 657M 9.96M 66.7M 25.85M 322M 25.92M 25.36M 1.11B	9.73M 11.14M 8.94M 8.33M 15.8M 1.06B 16.07M 108M 41.7M 520M 41.82M 40.91M 1.79B
Net income	353K 404K 324K 302K 573K 38.44M 582K 3.9M 1.51M 18.85M 1.52M 1.48M 64.97M	737K 843K 677K 631K 1.2M 80.29M 1.22M 8.15M 3.16M 39.38M 3.17M 3.1M 136M
Net Debt	5.77K 6.6K 5.3K 4.94K 9.36K 628K 9.52K 63.76K 24.71K 308K 24.78K 24.24K 1.06M	295K 338K 271K 253K 480K 32.19M 488K 3.27M 1.27M 15.79M 1.27M 1.24M 54.4M